ClinicalTrials.gg
CompletedNCT04693104Updated Jan 5, 2021

Intra-articular PVA Hydrogel in Knee Osteoarthritis

An interventional study of PVA Hydrogel and Synvisk-One® in Knee Osteoarthritis, sponsored by Rottapharm Biotech. Completed at 1 site in Poland. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Rottapharm Biotech · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Oct 2019, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Enrollment
68th of 72
43 · median 115
Started
2019
with 6 others
No phase
28 of 78
9 open now
Registered
35th of 78
by date

Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 68th largest by enrollment of the 72 interventional ones that give a count, is one of 7 that started in 2019, is one of 28 with no phase, and was the 35th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

This multicentre, prospective, randomized, double-blind, active-controlled, parallel group clinical investigation is aimed to assess the safety and the clinical performance over 6 months of a single intra-articular injection of PVA Hydrogel, novel polyvinyl alcohol preparation, as compared to hyalan G-F20, (Synvisc-One®) one of the most commonly used and best performing hyaluronic acid based products, in patients with symptomatic knee osteoarthitis (OA).

Read the detailed description

To compare the effects of a single intra-articular injection of a novel polyvinyl alcohol preparation (PVA Hydrogel) and hylan G-F20 (Synvisc-One®) in patients with symptomatic knee OA.

Patients with knee OA (ACR clinical and radiological criteria) symptoms for ≥6 months, insufficient/failed response to analgesics, K\&L stage II-III (x-Rays within past 12 months), a knee pain score of 4-9 (0-10 NRS) in the target knee and \<3 in the contralateral knee, will be enrolled in a randomised, controlled, double-blind, parallel group 26-week clinical investigation to receive a single intra-articular injection of PVA Hydrogel or Synvisc-One®. Safety (both at the injection site (primary end-point) and overall) and efficacy (change in pain in the target knee (0-10 NRS), WOMAC Osteoarthritis Index (total and subscales) and Patient's Global Assessment of knee OA (0-10 NRS)) will be evaluated.

After signing an informed consent, patients will be screened at least 7 days before randomisation, when they will received a single intra-articular injection of either PVA Hydrogel or Synvisc-One® (1:1 allocation ratio) and will be then seen for follow-up 1, 2 and 4 days (this latter just in case of AE occurrence at the target knee) and 2, 4, 8, 12, 18 and 26 weeks after IA injection.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated obtained before undergoing any clinical-investigation-related procedure.
  2. Male or female aged between 40 and 80 years.
  3. Documented diagnosis of primary OA of the knee, based on the clinical and radiological American College of Rheumatology (ACR) criteria for knee OA:

    • Knee pain,
    • X-ray osteophytes,
    • at least one of the following: (a) age >50 years; (b) morning stiffness \<30 minutes in duration; (c) crepitus on active motion.
  4. Grade II-III according to the Kellgren and Lawrence classification (X-ray evidence at enrolment or within the previous 12 months).
  5. Knee OA symptoms for at least six months.
  6. Failure to respond (i.e. did not respond sufficiently) to analgesics and/or regular NSAIDs, or proven intolerance to regular use of NSAIDs or to weak opioids analgesics.
  7. Presence of pain in the target knee, with a value ≥4 and ≤9 on the NRS, providing that pain in the contralateral knee I less than 3 (see also Exclusion Criteria n. 3).
  8. Ability and willingness to communicate, participate, and comply with the requirements and scheduled procedures of the clinical investigation.

Exclusion criteria

Exclusion Criteria:

(a) Medical history and Concomitant Diseases related criteria

  1. Presence of isolated or predominantly symptomatic patellofemoral OA of the knee (i.e. pain when climbing stairs or forcing the patient to extend his leg when sitting on a low sit).
  2. Presence of secondary osteoarthritis and/or other rheumatic diseases. In particular, history or presence of the following diseases should be excluded: septic arthritis, inflammatory joint disease, gout, recurrent episodes of pseudogout, Paget's disease of bone, articular fracture, ochronosis, acromegaly, haemocromatosis, Wilson's disease, primary osteochondromatosis.
  3. Contralateral (i.e. non-target) knee pain >3 on the NRS
  4. Any knee OA treatment for both knees (other than the clinical investigation viscosupplementation of the target knee) anticipated within the next 6 months.
  5. Presence of pain (any severity) in the ipsilateral and/or contralateral hip.
  6. Presence of disease of the spine or other lower extremity joints of sufficient severity to affect the clinical investigation assessments.
  7. Anterior cruciate ligament repair, reconstruction or injury in the target knee within the previous 3 years.
  8. Cartilage repair/surgery in the target knee within the previous 3 years.
  9. Any surgery in the lower limbs within the previous 12 months
  10. Any planned surgery of the lower limbs during the clinical investigation period.
  11. Significant articular deformities of the lower limbs, i.e. major dysplasia and congenital abnormalities.
  12. Presence of varus or valgus knee deformity ≥ 8°.
  13. History or presence of osteonecrosis in the lower limbs.
  14. Presence of any significant injury of the ipsilateral limb within the previous 6 months.
  15. Presence of joint effusion and/or infection at the target knee.
  16. Presence of local skin abnormalities (e.g. infection or disease) at the target knee.
  17. History or presence of knee joint infection secondary to previous intra-articular injections, or increased predisposition to infections.
  18. History or high risk of venous thromboembolism and/or venous or lymphatic stasis of the limb of the target knee.
  19. History of allergy or known to hyaluronic acid, to any of the components of the products under clinical investigation, or to paracetamol.
  20. History of hypersensitivity to avian proteins.
  21. Morbidly obese patients (≥35).
  22. Severe concomitant disease at any organ or apparatus (including acute or chronic infectious diseases) that may interfere with the free use and evaluation of the affected knee for the 6 months course of the clinical investigation and/or (with the exception of adequately treated or excised non basal cell or squamous cell cancer of the skin or in situ uterine cervical cancer) active within the previous 12 months.
  23. History of drug, alcohol, or other substance abuse, or other factors limiting the ability to cooperate during the clinical investigation.
  24. Any other disease and condition that, in the opinion of the principal investigators, may jeopardize the clinical investigation conduct according to the CIP or performance or safety assessments or may compromise the patients' safety or may place the patient at an undue risk by participating in the clinical investigation.

    (b) Previous or concomitant treatments

  25. Patients requiring systemic analgesics (including opiates)/NSAIDs for the target knee, or for indications other than OA pain at the target knee but likely to use these medications for more than 5 consecutive days, or for more than 10 non-consecutive days in one month, or unable to stop them during the 2 days preceding a clinic visit.
  26. Patients requiring topical analgesics/NSAIDs for the target knee.
  27. Patient requiring intra-articular into any joint or periarticular structure in the lower limb, or systemic corticosteroids (oral or injected for any indication).
  28. Patients who underwent tidal lavage of the knee joint(s) during the three months prior to randomization.
  29. Viscosupplementation in the lower limbs within the previous 12 months.
  30. Patients on SYSADOAs or a dietary supplement containing compounds considered specific for OA (e.g. glucosamine, chondroitin sulphate, diacerein) if the dosage has not been stable within the previous 3 months.
  31. Patients on anticoagulant treatment other than direct oral anticoagulants (DOACS).
  32. Non-pharmacological therapy for the lower extremities, unless stable for more than one month (and not to be substantially altered during the clinical investigation). Physical therapy is allowed.
  33. Patients using assistive devices other than a cane (walking stick) or knee brace.
  34. Concomitant participation in any clinical study/investigation or treatment with any drugs/treatments/devices within the previous 3 months or 5 of half-lives (whichever is longer).
  35. to use of hyaluronic acid.
  36. Contraindication to use of paracetamol. (c) Other
  37. For women of , not surgically sterile or :

    • Pregnancy (i.e. positive pregnancy test at screening) or breastfeeding;
    • Failure to agree to practice a highly effective method of for 3 months after the IA injection.
  38. For sexually active men with a female partner of childbearing potential: failure to use a reliable method of birth control for 3 months after the IA injection.

Randomization Criteria:

  1. Pain value in the target knee ≥4 and ≤9 on the NRS.
  2. Absence of joint effusion in the target knee.
  3. Absence of local skin abnormalities (e.g. infection or disease) at the target knee.
  4. No use of analgesics/NSAIDs during the 2 days preceding the Randomization Visit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    PVA Hydrogel

    PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection

    Device: PVA Hydrogel

  • Active comparator
    Synvisc-One®

    Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection

    Device: Synvisk-One®

Interventions

  • DevicePVA Hydrogel

    PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.

  • DeviceSynvisk-One®

    Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.

06

What researchers measure

Primary outcomes

  1. Adverse Events at the injection site (target knee)

    patient reported symptom and/or investigator detected clinical sign

    Time frame: 6 months

  2. Adverse Device Events

    AEs considered as related to the device and/or to the IA procedure.

    Time frame: 6 months

Secondary outcomes

  1. Device Deficiencies

    malfunctions, use errors and inadequate labelling occurred before, during or after the use of the devices

    Time frame: 6 months

  2. Adverse Events

    any AE irrespective of target knee involvement

    Time frame: 6 months

  3. Physical examination

    a complete physical examination will be carried out at all scheduled clinic visits and/or at any unscheduled/early termination visit in case of premature discontinuation. Clinically significant findings of the physical examination at screening will be documented as concomitant diseases. New findings or worsening of a finding at all visits following the screening visit will recorded as adverse events.

    Time frame: 6 months

  4. Blood pressure

    Systolic and diastolic blood pressure (mmHg)

    Time frame: 6 months

  5. Pulse rate

    Radial pulse rate (beats/minute)

    Time frame: 6 months

  6. Body temperature

    Body temperature will be assessed via a mouth thermometer (degrees Celsius (°C)

    Time frame: 6 months

  7. Knee pain

    0-10 NRS ("0=no pain" to "10=the worst possible pain") during past 48 hours

    Time frame: 6 months

  8. WOMAC Index

    tri-dimensional, disease-specific, self-administered, health status measure, to assess pain, stiffness and physical function in patients with knee OA, NRS format, version 3.1, 48 hours recall period

    Time frame: 6 months

  9. Patient's Global Assessment of knee OA

    overall judgment of efficacy ("Considering all the ways your knee osteoarthritis affects you, how would you rate the severity of your condition over the last week?" according to a 0-10 NRS scale, anchored at 0 = "I am feeling very well" and 10 = "I am feeling as bad as possible"

    Time frame: 6 months

  10. Rescue medication use

    Number of paracetamol tablets taken each day

    Time frame: 6 months

07

Study locations

1 site
  • Lubelskie Centrum Diagnostyczne
    Świdnik, 21-040, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in May 2020, 7 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 7 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2020
First posted
Jan 5, 2021
StartActual
Oct 1, 2019
Primary completionActual
May 20, 2020
CompletionActual
May 20, 2020
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04693104
Lead sponsor
Rottapharm Biotech
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Oct 1, 2019
Primary completion
May 20, 2020
Completion
May 20, 2020
Last update
Jan 5, 2021

Study contacts

Tomaz Blicharski
study director · Lubelskie Centrum Diagnostyczne, Swidnik, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion